Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
16/09/2026 02:53
BRIEF-Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection Sept 16 (Reuters) - Sino Biopharmaceutical Limited 1177.HK:
CHINA'S CDE ACCEPTS NEW DRUG APPLICATION FOR TQH2722 INJECTION 'IL-4R MONOCLONAL ANTIBODY'
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit